Compendium of Cancer Genome Aberrations

Changes

TestAMLtable (view source)

Revision as of 15:24, 4 November 2018

597 bytes removed ,  15:24, 4 November 2018
no edit summary
Line 5: Line 5:  
! Chromosome
 
! Chromosome
 
! AML Subtype
 
! AML Subtype
−
! Abnormality Type (Gain, Loss, CN-LOH)
+
! Abnormality Type (Amplification, Loss, CN-LOH)
 
! Region
 
! Region
 
! Relevant Genes (if known)
 
! Relevant Genes (if known)
 
! Clinical Significance
 
! Clinical Significance
 
! Level of Evidence
 
! Level of Evidence
−
! Reference
   
|-
 
|-
 
| 1
 
| 1
Line 19: Line 18:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 29, 30, 67-69, 102-104]
   
|-
 
|-
 
| 2
 
| 2
Line 28: Line 26:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 65, 100]
   
|-
 
|-
 
| 3
 
| 3
Line 37: Line 34:  
| D
 
| D
 
| 3
 
| 3
−
| [30, 57, 66]
   
|-
 
|-
 
| 4
 
| 4
Line 46: Line 42:  
| D
 
| D
 
| 3
 
| 3
−
| [67, 71, 105]
   
|-
 
|-
 
| 4
 
| 4
Line 55: Line 50:  
| D, P
 
| D, P
 
| 3
 
| 3
−
| [42, 45, 66]
   
|-
 
|-
 
| 5
 
| 5
Line 64: Line 58:  
| D
 
| D
 
| 1
 
| 1
−
| [24, 33, 45, 49, 57, 66, 77, 87, 88, 106-108]
   
|-
 
|-
 
| 6
 
| 6
Line 73: Line 66:  
| D
 
| D
 
| 3
 
| 3
−
| [29, 30, 102, 104]
   
|-
 
|-
 
| 7
 
| 7
Line 82: Line 74:  
| D
 
| D
 
| 3
 
| 3
−
| [67, 102, 109]
   
|-
 
|-
 
| 7
 
| 7
Line 91: Line 82:  
| D
 
| D
 
| 1
 
| 1
−
| [28, 57, 66, 110]
   
|-
 
|-
 
| 8
 
| 8
−
| complex karyotype AML
+
| AML with complex karyotype
 
| Amplification
 
| Amplification
 
| 8q24
 
| 8q24
Line 100: Line 90:  
| D, P
 
| D, P
 
| 3
 
| 3
−
| [24, 49, 61]
   
|-
 
|-
 
| 9
 
| 9
Line 109: Line 98:  
| D
 
| D
 
| 3
 
| 3
−
| [66, 67, 104]
   
|-
 
|-
 
| 11*
 
| 11*
−
| AML w complex karyotype
+
| AML with complex karyotype
 
| Amplification
 
| Amplification
 
| 11q23
 
| 11q23
Line 118: Line 106:  
| D, P
 
| D, P
 
| 3
 
| 3
−
| [49, 111]
   
|-
 
|-
 
| 11*
 
| 11*
Line 127: Line 114:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 30, 65, 102]
   
|-
 
|-
 
| 11
 
| 11
Line 136: Line 122:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 65-67, 102]
   
|-
 
|-
 
| 12
 
| 12
−
| AML, NK-AML, AML w complex karyotype, sAML
+
| AML, NK-AML, AML with complex karyotype, sAML
 
| Loss
 
| Loss
 
| 12p13.2
 
| 12p13.2
Line 145: Line 130:  
| D
 
| D
 
| 3
 
| 3
−
| [24, 30, 33, 49, 57, 61, 66, 77, 104, 108, 111-115]
   
|-
 
|-
 
| 13*
 
| 13*
−
| pAML, NK-AML, NPM1 mutated AML, FLT3-ITD pos AML, sAML
+
| pAML, NK-AML, ''NPM1'' mutated AML, FLT3-ITD positive AML, sAML
 
| CN-LOH
 
| CN-LOH
 
| 13q
 
| 13q
Line 154: Line 138:  
| D, P
 
| D, P
 
| 2
 
| 2
−
| [11, 28-31, 65-69, 102, 104, 109, 116-118]
   
|-
 
|-
 
| 16
 
| 16
−
| NK-AML, AML w complex karyotype, pAML, sAML
+
| NK-AML, AML with complex karyotype, pAML, sAML
 
| Loss
 
| Loss
 
| 16q
 
| 16q
Line 163: Line 146:  
| D
 
| D
 
| 3
 
| 3
−
| [29, 49, 61, 108]
   
|-
 
|-
 
| 17
 
| 17
Line 172: Line 154:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 28, 29, 65, 67, 102, 107]
   
|-
 
|-
 
| 17
 
| 17
−
| sAML, NK-AML, AML w complex karyotype, de novo AML
+
| sAML, NK-AML, AML with complex karyotype, ''de novo'' AML
 
| Loss
 
| Loss
 
| 17p
 
| 17p
Line 181: Line 162:  
| D, P
 
| D, P
 
| 1
 
| 1
−
| [24, 28, 29, 49, 61, 66, 88, 106-108, 114]
   
|-
 
|-
 
| 17
 
| 17
Line 190: Line 170:  
| D, P
 
| D, P
 
| 3
 
| 3
−
| [24, 28, 29, 47-49, 61, 66, 104, 111]
   
|-
 
|-
 
| 19*
 
| 19*
Line 199: Line 178:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 29, 30, 69, 102, 105]
   
|-
 
|-
 
| 20
 
| 20
Line 208: Line 186:  
| D
 
| D
 
| 3
 
| 3
−
| [24, 66, 119, 120]
   
|-
 
|-
 
| 21*
 
| 21*
−
| pAML, AML w complex karyotype
+
| pAML, AML with complex karyotype
 
| Amplification
 
| Amplification
 
| 21q22
 
| 21q22
Line 217: Line 194:  
| D, P, T
 
| D, P, T
 
| 3
 
| 3
−
| [49, 57, 61, 62, 121]
   
|-
 
|-
 
| 21*
 
| 21*
Line 226: Line 202:  
| D
 
| D
 
| 3
 
| 3
−
| [11, 29, 67, 70, 102-105]
   
|-
 
|-
 
| 21*
 
| 21*
Line 235: Line 210:  
| D
 
| D
 
| 3
 
| 3
−
| [57]
   
|-
 
|-
 
|}
 
|}
Retrieved from "https://ccga.io/index.php/Special:MobileDiff/5299"